Tumor of hematopoietic and lymphoid tissues

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:68347
Who is this for?
Show terms as
62Active trials20Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Tumors of hematopoietic and lymphoid tissues is a broad group of cancers that start in the blood-forming cells of the bone marrow or in the cells of the immune system (lymphoid tissue). These cancers are sometimes called blood cancers or liquid tumors. The main types include leukemias (cancers of blood cells), lymphomas (cancers of lymph nodes and lymphatic tissue), and myelomas (cancers of plasma cells in the bone marrow). Together, they are among the most common cancers worldwide. These diseases affect the body by disrupting the normal production and function of blood cells. Healthy blood cells — red cells, white cells, and platelets — are crowded out or replaced by abnormal cancer cells. This leads to symptoms like fatigue from anemia, frequent infections from a weakened immune system, and easy bruising or bleeding from low platelet counts. Swollen lymph nodes, bone pain, and unexplained weight loss are also common. Treatment depends heavily on the specific type of blood cancer. Options include chemotherapy, targeted therapy drugs, immunotherapy, radiation, and stem cell transplantation. Some types, like certain leukemias and lymphomas, can be cured with modern treatment. Others are managed as chronic conditions. Research is advancing rapidly, with many new FDA-approved therapies available in recent years, giving patients more options than ever before.

Key symptoms:

Extreme tiredness or fatigue that does not improve with restFrequent or unusual infectionsEasy bruising or bleeding, including nosebleeds or bleeding gumsSwollen lymph nodes in the neck, armpits, or groinUnexplained weight lossNight sweatsFever without a clear causeBone or joint painPale skinShortness of breathFeeling full quickly or abdominal discomfort due to an enlarged spleen or liverItchy skinNumbness or tingling in hands or feet (in some types)

Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Jul 2026Assessing DCog Short for Neurotoxicity in CAR-T

Beth Israel Deaconess Medical Center — NA

TrialNOT YET RECRUITING
Jun 2026Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

Hannah Choe, MD — PHASE2

TrialRECRUITING
Apr 2026Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

National Cancer Institute (NCI) — PHASE1

TrialRECRUITING
Mar 2026BY002 IIT Study in R/R Acute Leukemia

The First Affiliated Hospital of Soochow University — PHASE1

TrialRECRUITING
Mar 2026CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

St. Jude Children's Research Hospital — PHASE1

TrialRECRUITING
Mar 2026Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

ModeX Therapeutics, An OPKO Health Company — PHASE1, PHASE2

TrialRECRUITING
Feb 2026Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).

Gyala Therapeutics — PHASE1, PHASE2

TrialRECRUITING
Jan 2026This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.

Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology — PHASE1, PHASE2

TrialNOT YET RECRUITING
Dec 2025Early Versus Late Stopping of Antibiotics in Adults With High-risk Hematological Malignancies/Receiving Cellular Therapies and Fever

Peter MacCallum Cancer Centre, Australia — NA

TrialRECRUITING
Nov 2025What is the Impact of TKI on Thyroid Function in CML Patients?

Assiut University

TrialNOT YET RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Tumor of hematopoietic and lymphoid tissues.

20 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

20 recruitingView all trials with filters →
Phase 31 trial
RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease
Phase 3
Active
PI: John Raemaekers, MD, PhD (Universitair Medisch Centrum St. Radboud - Nijmege) · Sites: Antwerp; Bruges +54 more · Age: 1570 yrs
Phase 23 trials
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
Phase 2
Active
PI: Mitchell R. Smith, MD, PhD (Fox Chase Cancer Center) · Sites: Anchorage, Alaska; Anchorage, Alaska +416 more · Age: 18120 yrs
Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant
Phase 2
Active
PI: Jean Roy, MD (Ciusss de L'Est de l'Île de Montréal) · Sites: Montreal, Quebec · Age: 1865 yrs
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
Phase 2
Actively Recruiting
PI: Ghayas Issa, MD (M.D. Anderson Cancer Center) · Sites: New York, New York; Houston, Texas · Age: 1299 yrs
Other16 trials
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
Active
PI: Ryotaro Nakamura (City of Hope Medical Center) · Sites: Duarte, California · Age: 1899 yrs
Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy
Actively Recruiting
PI: Aleksander Chojecki, MD (Wake Forest University Health Sciences) · Sites: Charlotte, North Carolina · Age: 1899 yrs
Registry of Older Patients With Cancer
Actively Recruiting
PI: Hyman Muss, MD (UNC Lineberger Comprehensive Cancer Center) · Sites: Boone, North Carolina; Chapel Hill, North Carolina +5 more · Age: 6599 yrs
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Actively Recruiting
PI: Paul Armistead, MD (UNC Lineberger Comprehensive Cancer Center) · Sites: Chapel Hill, North Carolina · Age: 18120 yrs
Prospective Cohort With Hemopathy in Languedoc-Roussillon
Actively Recruiting
PI: GUILLAUME CARTRON (University Hospital, Montpellier) · Sites: Montpellier · Age: 1899 yrs
Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis
Actively Recruiting
· Sites: Paris; Paris +1 more · Age: 1100 yrs
Breath Analysis for the Detection of Invasive Fungal Infections
Actively Recruiting
PI: Jeremy Deuel, PD Dr. (University of Zurich) · Sites: Zurich, Canton of Zurich · Age: 1899 yrs
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
Actively Recruiting
PI: Bouthaina S Dabaja (M.D. Anderson Cancer Center) · Sites: Houston, Texas · Age: 1899 yrs
Better Leukemia Diagnostics Through AI (BELUGA)
Actively Recruiting
PI: Wolfgang Kern, Prof. Dr. (MLL Munich Leukemia Laboratory) · Sites: Munich, Bavaria · Age: 1899 yrs
Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment
Enrolling by Invitation
PI: Steven A Rosenberg, M.D. (National Cancer Institute (NCI)) · Sites: Bethesda, Maryland · Age: 1899 yrs
Assessing the Presence of CT-DNA in Lymphoma Associated HLH
Actively Recruiting
· Sites: Nottingham, Nottinghamshire · Age: 1899 yrs
Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia
Actively Recruiting
PI: Roni Tamari, MD (Memorial Sloan Kettering Cancer Center) · Sites: Hartford, Connecticut; New York, New York +1 more · Age: 1880 yrs
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
Actively Recruiting
PI: Kenneth Offit, MD (Memorial Sloan Kettering Cancer Center) · Sites: Basking Ridge, New Jersey; Middletown, New Jersey +4 more
Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
Enrolling by Invitation
PI: James N Kochenderfer, M.D. (National Cancer Institute (NCI)) · Sites: Bethesda, Maryland · Age: 1899 yrs
AMH as a Predictor of Infertility Risk in Children With Cancer (CHANCE)
Actively Recruiting
PI: Isabelle Demeestere, PhD (Erasme ULB- Belgium) · Sites: Montegnée, Liège; Antwerp +8 more · Age: 314 yrs
Solving Riddles Through Sequencing
Actively Recruiting
· Sites: Munich · Age: 1899 yrs

Specialists

20 foundView all specialists →
RM
Robert G Bociek, MD
OMAHA, NE
Specialist
PI on 1 active trial
HT
Hussein A Tawbi
HOUSTON, TX
Specialist
PI on 2 active trials
TM
Thomas G. Martin, MD
Specialist
PI on 4 active trials
RN
Ryotaro Nakamura
Duarte, California
Specialist

Rare Disease Specialist

PI on 6 active trials
PM
Paul Martin
Specialist
PI on 3 active trials73 Tumor of hematopoietic and lymphoid tissues publications
SM
Susan K. Parsons, MD, MRP
Specialist
PI on 1 active trial
AW
Ann Woolfrey
SEATTLE, WA
Specialist
PI on 5 active trials
CM
Casey O'Connell, MD
Los Angeles, California
Specialist

Rare Disease Specialist

PI on 3 active trials
DM
Divaya Bhutani, M.D.
NEW YORK, NY
Specialist
PI on 1 active trial
JH
Joerg Herrmann
ROCHESTER, MN
Specialist
PI on 2 active trials
LJ
Lian Jiang
GREENVILLE, NC
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Tumor of hematopoietic and lymphoid tissues.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Tumor of hematopoietic and lymphoid tissuesForum →

No community posts yet. Be the first to share your experience with Tumor of hematopoietic and lymphoid tissues.

Start the conversation →

Latest news about Tumor of hematopoietic and lymphoid tissues

Disease timeline:

New recruiting trial: Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers

A new clinical trial is recruiting patients for Tumor of hematopoietic and lymphoid tissues

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What specific type of blood cancer do I have, and what does that mean for my treatment and outlook?,What genetic or molecular tests have been done on my cancer, and how do the results affect my treatment options?,Is my cancer potentially curable, or is the goal to manage it long-term?,What are the most important side effects of the recommended treatment, and how will they be managed?,Should I or my family members be tested for inherited gene mutations that increase cancer risk?,Are there clinical trials I might be eligible for?,What signs or symptoms should prompt me to call you or go to the emergency room right away?

Common questions about Tumor of hematopoietic and lymphoid tissues

What is Tumor of hematopoietic and lymphoid tissues?

Tumors of hematopoietic and lymphoid tissues is a broad group of cancers that start in the blood-forming cells of the bone marrow or in the cells of the immune system (lymphoid tissue). These cancers are sometimes called blood cancers or liquid tumors. The main types include leukemias (cancers of blood cells), lymphomas (cancers of lymph nodes and lymphatic tissue), and myelomas (cancers of plasma cells in the bone marrow). Together, they are among the most common cancers worldwide. These diseases affect the body by disrupting the normal production and function of blood cells. Healthy blood c

Are there clinical trials for Tumor of hematopoietic and lymphoid tissues?

Yes — 20 recruiting clinical trials are currently listed for Tumor of hematopoietic and lymphoid tissues on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Tumor of hematopoietic and lymphoid tissues?

20 specialists and care centers treating Tumor of hematopoietic and lymphoid tissues are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.